ReviewMicroorganisms2022
The Immunobiology of Nipah Virus.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- A rapid detection of Nipah virus nucleocapsid antigen in inactivated viral cultures.Emerging microbes & infections · 2026Article
- Ensemble Docking, MD, and MM/PBSA Identify Flavonoids as Putative Modulators of EFNB2/B3-Nipah Virus G Interaction.International journal of molecular sciences · 2026Article
- Nipah virus matrix protein promotes NF-κB activation by targeting multiple signaling modulators.Journal of virology · 2026Article
- Comprehensive mapping of human CD4Cell reports. Medicine · 2026Article
- Persistent T Cell Immunity Following Nipah Virus Infection: Evidence From Malaysian Survivors.The Journal of infectious diseases · 2026Article
- The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness.PLoS pathogens · 2026Review
- Article
- Protective immunity in hamsters from an oral Nipah vaccine correlates with pseudovirus neutralising antibody titre.Scientific reports · 2026Article
- Emerging Vector-Borne Nipah Virus Infection: Unexplored Hazards, Diagnostic Challenges, and the Potential of Phytomedicine-Based Therapeutics.Current pharmaceutical design · 2026Review
- Current knowledge on the host-pathogen interactions of henipaviruses and novel platforms to enable further characterisation.EBioMedicine · 2026Review
- Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications.Cellular and molecular neurobiology · 2025Review
- Article
- Review
- Nipah virus: pathogenesis, genome, diagnosis, and treatment.Applied microbiology and biotechnology · 2025Review
- Immunoinformatics-driven design of a multi-epitope vaccine against nipah virus: A promising approach for global health protection.Journal, genetic engineering & biotechnology · 2025Article
- Histopathological and immunohistochemical characterization of lesions in the golden Syrian hamster model of Nipah virus infection (Bangladesh strain).Frontiers in veterinary science · 2025Article
- An Updated Review on Nipah Virus Infection with a Focus on Encephalitis, Vasculitis, and Therapeutic Approaches.Current topics in medicinal chemistry · 2025Review
- Article
- Repurposing of approved drugs towards Nipah virus treatment: an in silico docking, molecular dynamics simulation and a MM/GBSA approach.In silico pharmacology · 2025Article
- Establishing an immune correlate of protection for Nipah virus in nonhuman primates.NPJ vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Nipah virus (NiV) is a highly lethal zoonotic paramyxovirus that emerged in Malaysia in 1998. It is a human pathogen capable of causing severe respiratory infection and encephalitis. The natural reservoir of NiV, Pteropus fruit bats, remains a continuous virus source for future outbreaks, although infection in the bats is largely asymptomatic. NiV provokes serious disease in various mammalian species. In the recent human NiV outbreaks in Bangladesh and India, both bats-to-human and human-to-human transmissions have been observed. NiV has been demonstrated to interfere with the innate immune response via interferon type I signaling, promoting viral dissemination and preventing antiviral response. Studies of humoral immunity in infected NiV patients and animal models have shown that NiV-specific antibodies were produced upon infection and were protective. Studies on cellular immunity response to NiV infection in human and animal models also found that the adaptive immune response, specifically CD4+ and CD8+ T cells, was stimulated upon NiV infection. The experimental vaccines and therapeutic strategies developed have provided insights into the immunological requirements for the development of successful medical countermeasures against NiV. This review summarizes the current understanding of NiV pathogenesis and innate and adaptive immune responses induced upon infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.